BioSpace News Archive

LEXEO Therapeutics today announced that the European Commission has granted Orphan Drug Designation to LX1004 for the treatment of CLN2 Batten disease.

Aligos Therapeutics, Inc. today announced that the Company will make an oral presentation at the Cambridge Healthtech Institute’s 20th Annual Discovery on Target Conference being held October 17-20, 2022 in Boston, MA.

AnPac Bio-Medical Science Co., Ltd. today announced that it plans to change the ratio of the Company’s American Depositary Shares (“ADSs”) to its Class A ordinary shares from one (1) ADS representing one (1) Class A ordinary share to one (1) ADS representing twenty (20) Class A ordinary shares.

HemoShear Therapeutics, Inc. today announced that it will participate in SVB Leerink Biopharma Private Company Connect being held virtually October 26-27.

OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, announced that the Company is scheduled to release its third quarter 2022 financial results on Monday, October 31, 2022, after the market closes.

Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced that it has approved 4 additional clinical trial sites for IMX-110 clinical trials, complementing existing soft tissue sarcoma lead clinical trial site in California.

Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”) today announced the publication of abstracts for two posters that will be presented at the upcoming 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (“2022 ENA”), taking place from October 26th to October 28th, 2022 in Barcelona, Spain.

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) announced today the company will present new data and research at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting, being held October 21-26 in Charlotte, NC.

Medtronic plc, the global leader in medical technology, is introducing a new program called My Insights exclusively made for individuals using the MiniMed™ 770G system.

RhythMedix, a leader in remote cardiac monitoring and proprietary arrhythmia detection algorithms, today announced expanded modalities for its RhythmStar® System (RhythmStar).